HCW Biologics is a clinical-stage company advancing development of transformative immunotherapies to lengthen healthspan by disrupting inflammaging.
HCW Biologics is a clinical-stage company advancing the development of novel immunotherapeutics designed to disrupt the link between chronic, low-grade inflammation and age-related disorders. This field, known as inflammaging, targets the unresolved inflammatory responses and chronic, low-grade inflammation associated with advancing age and believed to be a significant contributing factor to cancer and several chronic conditions, including cardiovascular disease, diabetes, neurodegenerative disease, and autoimmune disease.
The core of HCW’s discovery and development efforts revolves around the company’s internally developed Tissue FactOr-Based FusIon (TOBI™) platform, which is designed to engineer multi-functional fusion protein molecules and protein complexes. The technology employs a Tissue Factor (TF) scaffold that can be packaged with multiple protein targets, including cytokines, chemokines, ligands, receptors, and single-chain antibodies, carefully selected to work in tandem to stimulate and target desired immune responses and inhibit unwanted inflammation.